Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology.
High growth potential and slightly overvalued.
Share Price & News
How has Ocular Therapeutix's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OCUL's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: OCUL exceeded the US Pharmaceuticals industry which returned 6.3% over the past year.
Return vs Market: OCUL matched the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Ocular Therapeutix's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StIs Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?
1 month ago | Simply Wall StHow Should Investors React To Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) CEO Pay?
2 months ago | Simply Wall StOcular Therapeutix, Inc. (NASDAQ:OCUL) Is Expected To Breakeven
Is Ocular Therapeutix undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OCUL ($5.65) is trading below our estimate of fair value ($28.5)
Significantly Below Fair Value: OCUL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OCUL is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: OCUL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OCUL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OCUL is overvalued based on its PB Ratio (24x) compared to the US Pharmaceuticals industry average (3x).
How is Ocular Therapeutix forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OCUL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: OCUL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: OCUL's is expected to become profitable in the next 3 years.
Revenue vs Market: OCUL's revenue (45.9% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: OCUL's revenue (45.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OCUL's Return on Equity is forecast to be high in 3 years time
How has Ocular Therapeutix performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OCUL is currently unprofitable.
Growing Profit Margin: OCUL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OCUL is unprofitable, and losses have increased over the past 5 years at a rate of -18.6% per year.
Accelerating Growth: Unable to compare OCUL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCUL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.4%).
Return on Equity
High ROE: OCUL has a negative Return on Equity (-688.03%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Ocular Therapeutix's financial position?
Financial Position Analysis
Short Term Liabilities: OCUL's short term assets ($69.6M) exceed its short term liabilities ($11.0M).
Long Term Liabilities: OCUL's short term assets ($69.6M) exceed its long term liabilities ($66.4M).
Debt to Equity History and Analysis
Debt Level: OCUL's debt to equity ratio (425.6%) is considered high.
Reducing Debt: OCUL's debt to equity ratio has increased from 22.6% to 425.6% over the past 5 years.
Inventory Level: OCUL has a high level of physical assets or inventory.
Debt Coverage by Assets: OCUL's debt is covered by short term assets (assets are 1.4x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OCUL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OCUL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Ocular Therapeutix's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate OCUL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate OCUL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OCUL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OCUL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OCUL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Antony Mattessich (52yo)
Mr. Antony Mattessich has been the Chief Executive Officer and President of Ocular Therapeutix, Inc. since July 26, 2017. Mr. Mattessich serves as Managing Director of Mundipharma International Limited. He ...
CEO Compensation Analysis
Compensation vs Market: Antony's total compensation ($USD2.63M) is above average for companies of similar size in the US market ($USD1.11M).
Compensation vs Earnings: Antony's compensation has been consistent with company performance over the past year.
|Chief Financial Officer||2.4yrs||US$982.03k||0.050% $123.6k|
|Chief Operations Officer||0.6yrs||no data||no data|
|Chief Scientific Officer||0yrs||no data||no data|
|General Counsel & Chief Intellectual Property Counsel||2.2yrs||no data||no data|
|Vice President of Global Sales & Marketing||0yrs||no data||no data|
|Senior Vice President of Business & Corporate Development||1.1yrs||no data||no data|
|Director of Human Resources||2.3yrs||no data||no data|
|Senior Vice President of Commercial||2.1yrs||no data||no data|
|Chief Medical Officer||2.4yrs||US$1.05m||0.053% $132.0k|
Experienced Management: OCUL's management team is considered experienced (2.2 years average tenure).
|Independent Chairman||0.5yrs||US$197.98k||no data|
|Independent Director||7.3yrs||US$160.48k||0.21% $514.0k|
|Lead Independent Director||0yrs||US$175.48k||0.092% $226.4k|
|Director||0.9yrs||no data||0.0094% $23.1k|
|Independent Director||4.4yrs||US$152.98k||0.050% $123.4k|
|Director||0.7yrs||no data||no data|
Experienced Board: OCUL's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.1%.
Ocular Therapeutix, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Ocular Therapeutix, Inc.
- Ticker: OCUL
- Exchange: NasdaqGM
- Founded: 2006
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$247.129m
- Shares outstanding: 48.08m
- Website: https://www.ocutx.com
Number of Employees
- Ocular Therapeutix, Inc.
- 15 Crosby Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|OCUL||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jul 2014|
|0OT||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2014|
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant for the treatment of wet age-related macular degeneration(AMD); and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. Its various preclinical programs include OTX-BPI for the treatment of acute ocular pain; OTX-BSI to treat post-operative Pain, and inflammation and bacterial infection; OTX-KTO for the treatment of allergy; and OTX-CSI to treat chronic dry-eye. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds to address conditions of the eye. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/25 01:28|
|End of Day Share Price||2020/02/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.